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ABSTRACT
Objective: Bone disease is a common comorbidity in patients with cystic fibrosis (CF). 
We sought to determine risk factors and identify potential biochemical markers for CF-
related bone disease (CFBD) in a unique cohort of CF patients with end-stage lung 
disease undergoing lung transplantation (LTx) evaluation. Methods: All of the CF patients 
who were evaluated for LTx at our center between November of 1992 and December of 
2010 were included in the study. Clinical data and biochemical markers of bone turnover, 
as well as bone mineral density (BMD) at the lumbar spine and femoral neck, were 
evaluated. Spearman’s rho and multivariate logistic regression analysis were used. 
Results: A total of 102 adult CF patients were evaluated. The mean age was 28.1 years 
(95% CI: 26.7-29.5), and the mean body mass index was 17.5 kg/m2 (95% CI: 17.2-18.2). 
Mean T-scores were −2.3 and −1.9 at the lumbar spine and femoral neck, respectively, 
being lower in males than in females (−2.7 vs. −2.0 at the lumbar spine and −2.2 vs. −1.7 
at the femoral neck). Overall, 52% had a T-score of < −2.5 at either skeletal site. The 
homozygous Phe508del genotype was found in 57% of patients without osteoporosis 
and in 60% of those with low BMD. Mean T-scores were not particularly low in patients 
with severe CFTR mutations. Although the BMI correlated with T-scores at the femoral 
neck and lumbar spine, serum 25-hydroxyvitamin D and parathyroid hormone levels 
did not. Conclusions: CFBD is common in CF patients with end-stage lung disease, 
particularly in males and patients with a low BMI. It appears that CF mutation status 
does not correlate with CFBD. In addition, it appears that low BMD does not correlate 
with other risk factors or biochemical parameters. The prevalence of CFBD appears to 
have recently decreased, most likely reflecting increased efforts at earlier diagnosis and 
treatment. 
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INTRODUCTION
Cystic fibrosis (CF) is a common life-shortening 
autosomal recessive genetic disorder that affects multiple 
organs and is caused by mutations in the CFTR gene, 
which encodes primarily for a chloride ion channel.(1) 
CF-related comorbidities reduce health-related quality 
of life and pose an ongoing challenge for patients and 
treating physicians. The cause of CF-related bone disease 
(CFBD) is likely multifactorial; CFBD is due to both 
suboptimal peak bone mass acquisition and increased 
bone loss during adulthood, affecting up to 20% of 
adolescent patients and 55-65% of patients 45 years of 
age or older.(2) Known risk factors for the development 
of CFBD are male sex, low body mass index (BMI), 
malnutrition, advanced lung disease, and systemic 
corticosteroid therapy. In fact, several factors contribute 
to the etiology of CFBD: chronic inflammation/infection, 
exocrine pancreatic insufficiency/malnutrition, low levels 
of anabolic hormones (insulin and IGF-I), low levels of sex 
hormones (estradiol and testosterone), and lack of physical 
activity.(3-10) In addition, CFTR protein dysfunction has 
recently been shown to affect bone-forming osteoblasts 
directly by reducing the production of osteoprotegerin 
and COX-2 metabolite prostaglandin E2, both of which 
are mediators of osteogenesis.(11) 
The objective of the present study was to assess 
the frequency of CFBD in a unique cohort of adult CF 
patients with end-stage lung disease evaluated for lung 
transplantation (LTx) at our center over nearly two decades, 
in order to gain a deeper understanding of contributing 
factors to CFBD, identify potential biochemical markers 
for CFBD, and assess changes in disease severity and 
therapies over time. 
METHODS
All adult CF patients (18 years of age or older) evaluated 
for LTx at the University Hospital of Zurich between 
November of 1992 and December of 2010 were included 
in the study. Referral and selection of LTx candidates 
at our center were done in accordance with published 
International Society for Heart and Lung Transplantation 
guidelines.(12) Data on CFTR mutation status and patient 
clinical status (including parameters such as age, sex, 
height, weight, BMI, percent predicted FEV1 [FEV1%], 
six-minute walk distance [6MWD], infectious exacerbations 
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in the previous year, and CF-related diabetes mellitus 
[CFRD]) were collected and tabulated. The 5-year 
survival rate was estimated in accordance with Liou et 
al.(13) In addition, patient medical records were reviewed 
for inhaled corticosteroid therapy, systemic corticosteroid 
therapy, vitamin D supplementation (at least 800 U per 
day), and bisphosphonate therapy. The following serum 
levels were measured: C-reactive protein, creatinine, 
albumin, fasting glucose, hemoglobin A1c, calcium 
(values being subsequently corrected for albumin by 
the following formula: measured calcium − 0.025 × 
albumin + 1), phosphate, bone alkaline phosphatase, 
25-hydroxyvitamin D (25(OH)D), parathyroid hormone 
(PTH), osteocalcin, testosterone (in males), and estradiol 
(in females). In a morning spot urine sample, calcium-
to-creatinine and deoxypyridinoline-to-creatinine ratios 
were determined. Creatinine was also measured in 
a 24-h urine collection in order to estimate skeletal 
muscle mass and glomerular filtration rate (GFR). 
The Cockcroft and Gault equation was used in order 
to calculate GFR, as proposed by Soulsby et al.(14) The 
relative time to first evaluation for LTx was calculated and 
used for multivariate regression analysis. In addition, 
bone mineral density (BMD) was measured by dual-
energy X-ray absorptiometry (DXA) and quantitative 
digital radiography (Hologic® DXA System; Hologic, 
Inc., Marlborough, MA, USA) at the femoral neck and 
lumbar spine, respectively, T-scores being calculated 
for both sites. Osteoporosis was defined in accordance 
with the World Health Organization BMD criteria as a 
T-score of ≤ −2.5, whereas osteopenia was defined 
as a T-score between −1.0 and −2.5.(15) 
Clinical and biochemical data are reported as means 
and 95% confidence intervals. The following groups 
of patients were evaluated: 1) females and males; 2) 
patients with osteoporosis (i.e., those with a T-score 
of ≤ −2.5 at either skeletal site) and patients without 
osteoporosis; and 3) patients evaluated earlier in the 
study period and patients evaluated later in the study 
period. For group comparisons, the Mann-Whitney test 
and the Kruskal-Wallis test were used, Fisher’s exact 
test or the chi-square test being used for categorical 
variables. Continuous variables were correlated by 
using Spearman’s rho. Univariate and multivariate 
logistic regression models were used in order to analyze 
osteoporosis (overall osteoporosis, lumbar spine 
osteoporosis, and femoral neck osteoporosis) and sex, 
as well as the relative time to evaluation for LTx and 
clinical parameters (BMI, FEV1%, 6MWD, CFRD, 25(OH)
D levels, phosphate levels, calcium levels, and protein 
levels). All statistical analyses were performed with the 
IBM SPSS Statistics software package, version 23.0 (IBM 
Corporation, Armonk, NY, USA). For all analyses, values 
of p < 0.05 were considered significant. The Research 
Ethics Committee of the Canton of Zurich approved this 
retrospective study (Protocol no. EK-1593). 
RESULTS
A total of 102 adult CF lung transplant candidates were 
included in the present study. The clinical characteristics 
of the study patients are shown in Table 1. 
BMD values as measured by DXA were available for 
all patients. Of those, 8 (8%) showed normal bone 
mass, 41 (40%) had osteopenia, and 53 (52%) had 
osteoporosis at either skeletal site. Mean T-scores at 
the femoral neck and lumbar spine were −1.9 (95% CI: 
1.73 to −2.10) and −2.3 (95% CI: −2.09 to −2.55), 
respectively, being lower in males than in females (p 
= 0.007 and p = 0.004, respectively; Figure 1). 
There were no differences in clinical parameters 
(or medication use) between males and females, the 
exception being height and weight (Table 1). The mean 
BMI was lower in patients with osteoporosis than in 
those without (17.4 kg/m2 vs. 18.1 kg/m2; p = 0.007; 
Table 2). No differences were found between the 
subgroups of patients with and without osteoporosis 
regarding FEV1%, 6MWD, frequency of CF exacerbations 
in the previous year, use of medications, presence of 
exocrine pancreatic insufficiency, or CFRD (Table 2). 
Table 3 shows biochemical parameters in all CF 
patients included in the study, by osteoporosis status 
(i.e., with or without osteoporosis). Although there 
were no significant differences between the two 
groups of patients, those with low T-scores (defining 
osteoporosis in the elderly) were more likely to have 
an increased calcium-to-creatinine ratio in a fasting 
spot urine sample (p = 0.04). In particular, there was 
no difference in serum levels of calcium, phosphate, 
25(OH)D, or PTH. Borderline high (albumin-corrected) 
calcium levels were found in 8 patients, and PTH levels 
> 65 ng/L (indicating secondary hyperparathyroidism 
in patients with low-normal serum calcium levels) 
were found in 11 (Table 3). Correlations of PTH 
levels with 25(OH)D and calcium levels are shown in 
Figure 2. Although PTH levels correlated significantly 
with (albumin-corrected) calcium levels (Spearman’s 
rho: −0.40; p < 0.001), they did not correlate with 
25(OH)D levels, age, creatinine levels, GFR, albumin 
levels, urinary calcium-to-creatinine ratio, urinary 
deoxypyridinoline-to-creatinine ratio, or 24-h urinary 
creatinine levels. Serum levels of PTH were not increased 
in a substantial number of patients with decreased 
serum levels of 25(OH)D. In addition, serum PTH levels 
were not associated with increased bone resorption 
markers or low BMD. 
As can be seen in Table 2, 50 patients (49%) were 
receiving vitamin D supplementation (4,000 IU plus 
multivitamin supplementation including vitamins A, 
D, E, and K), and 11 patients (11%) were receiving 
bisphosphonate therapy; 48 (47%) used inhaled 
corticosteroids on a regular basis, and 33 (32%) were 
on long-term systemic corticosteroid therapy. Patients 
using systemic corticosteroids were more likely to 
have low BMD (p = 0.023). A low BMI was found 
to correlate with low BMD (p = 0.004). Of the 102 
patients included in the study, 97 (95%) had exocrine 
pancreatic insufficiency and were receiving pancreatic 
enzyme supplementation (the dose of which varied 
depending on their diet). 
CF mutation status was known in 84 patients. Of 
those, 51 (61%) had a severe mutation (Table 2). 
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Table 1. Clinical characteristics of the cystic fibrosis patients included in the study.a
Characteristic Total sample Female CF 
patients
Male CF patients p
N = 102 
(100%)
n = 53 (52%) n = 49 (48%)
Age, years 28.1 (26.7-29.5) 27.5 (25.7-29.3) 28.8 (26.6-31.0)
Height, cm 166 (164-167) 161 (160-164) 170 (168-172) < 0.0001
Weight, kg 48 (47-50) 47 (45-49) 50 (48-53) 0.01
BMI, kg/m2 17.5 (17.2-18.2) 18.0 (17.2-18.9) 17.4 (16.8-18.0)
FEV1, % predicted 25 (24-27) 27 (24-29) 24 (22-26)
Relative time to first evaluation, years 9.9 (8.9-10.9) 10.4 (9.0-11.8) 9.3 (8.0-10.7)
Estimated 5-year survival, % 30 (28-33) 31 (27-35) 30 (28-33)
Osteoporosis, no/yes, n(%) 49/53 (48/52) 30/23 (57/43) 19/30 (39/61)
T-score at the lumbar spine −2.3 (−2.1 to 
−2.6)
−1.99 (−1.72 to 
−2.26)
−2.70 (−2.34 to 
−3.05)
0.004
BMD at the lumbar spine
Normal (T-scores > −1), n (%) 11 (11) 11 (21) 8 (16)
Osteopenia (T-scores ranging from −1 to −2.4), 
n (%) 
41 (42) 30 (59) 25 (49)
Osteoporosis (T-scores of ≤ −2.5), n (%) 45 (47) 10 (20) 18 (35)
T-score at the femoral neck −1.9  
(−1.7 to −2.1)
−1.67  
(−1.45 to −1.89)
−2.19  
(−1.9 to −2.48)
0.007
BMD at the femoral neck
Normal (T-scores > −1), n (%) 16 (16) 8 (16) 3 (7)
Osteopenia (T-scores ranging from −1 to −2.4), 
n (%) 
54 (55) 25 (49) 16 (35)
Osteoporosis (T-scores of ≤ −2.5), n (%) 28 (29) 18 (35) 27 (59)
CF: cystic fibrosis; BMI: body mass index; and BMD: bone mineral density. aValues expressed as mean (95% CI), 
except where otherwise indicated. 
Figure 1. T-scores at the femoral neck and lumbar spine, by gender and CFTR gene mutation. 
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With regard to CFTR mutation status (severe vs. mild 
mutations), no differences were found between the 
two regarding BMD. 
As can be seen in Table 2, comparisons were made 
between CF patients evaluated for LTx in the 1992-
2003 period (n = 51) and those evaluated for LTx in 
the 2004-2010 period (n = 51). Osteoporosis was 
much more common in the earlier era (n = 34; 65% 
vs. n = 19; 36.5%), whereas osteopenia was more 
common in the later era (n = 14; 27% vs. n = 27; 
52%). In addition, the 51 patients evaluated in the 
later era had a higher BMI (18.5 kg/m2 vs. 17 kg/m2; 
p = 0.007). Furthermore, vitamin D supplementation 
and bisphosphonate therapy were more common in 
the later era than in the earlier era (n = 35; 67% 
vs. n = 15; 29% and n = 9; 17.3% vs. n = 2; 4%, 
respectively). Moreover, CFRD was more frequently 
diagnosed (and subsequently treated with insulin) in 
the later era (n = 40; 77% vs. n = 28; 54%). 
In the multivariate analysis, the overall prevalence 
of osteoporosis was lower in the later era (OR = 0.88; 
95% CI: 0.80-0.96; p = 0.005), as was the prevalence 
of osteoporosis at the femoral neck (OR = 0.76; 95% 
CI: 0.63-0.92; p = 0.05). A high FEV1% was found to 
be a negative predictor of femoral neck osteoporosis 
(OR = 0.88; 95% CI: 0.79-0.98; p = 0.03). Males were 
more likely to have osteoporosis at the lumbar spine 
than were females (OR = 2.68; 95% CI: 1.13-6.35; p 
= 0.03). A low BMI was found to be a positive predictor 
of osteoporosis (OR = 0.75; 95% CI: 0.58-0.98; p 
= 0.003) and lumbar spine osteoporosis (OR = 0.70; 
95% CI: 0.54-0.91; p = 0.007). Mean T-scores at the 
Table 2. Clinical characteristics of the cystic fibrosis included in the study, by osteoporosis status (i.e., with or without 
osteoporosis) and era of evaluation (i.e., earlier or later in the study period).a
Characteristic Osteoporosis Era of evaluation p
Without With First 51 
patients
Last 51 
patientsn = 49 (48%) n = 53 (52%)
T-score at the lumbar spine −1.52 
(−1.31 to −1.72)
−3.15−2.90 to 
−3.4)
−2.56 
(−2.18 to −2.94)
−2.11 
(−1.85 to −2.38)
0.02
T-score at the femoral neck −1.29 
(−1.11 to −1.47)
−2.55 
(−2.35 to −2.75)
−2.29 
(−2.01 to −2.57)
−1.58 
(−1.37 to −1.79)
< 0.0001
Relative time to first evaluation, 
years
11.7 
(10.3-13.0)
8.2 
(7.0-9.5)
5.7 
(4.8-6.5)
14.1 
(13.5-14.7)
Sex, F/M, n (%) 30/19 
(61/39)
23/30 
(43/57)
24/27 
(47/53)
29/22 
(57/43)
Age, years 27.7 
(25.6-29.9)
28.4 
(26.6-30.3)
28.0 
(26.1-29.8)
28.3 
(26.2-30.4)
BMI, kg/m2 18.1 
(17.6-18.6)
17.4 
(16.5-18.3)
17.0 
(16.6-17.4)
18.5 
(17.6-19.4)
0.001
FEV1, % predicted 26 
(24-28)
25 
(22-27)
0.9 
(0.7-0.9)
1.2 
(0.5-1.8)
6MWD, m 367 
(336-398)
339 
(301-378)
332 
(300-366)
376 
(340-413)
0.04
CF exacerbation in the previous 
year
4.4 (4.2-4.7) 4.3 (3.9-4.6) 4.3 (4.0-4.5) 4.5 (4.1-4.8)
Prednisone use, no/yes, n (%) 37/12 (76/23) 29/21b (58/42) 32/16b (63/37) 34/17 (67/33)
Inhaled corticosteroid use, no/
yes, n (%)
28/21 (57/43) 23/27b (46/54) 23/25b (45/55) 28/23 (55/45)
Vitamin D supplementation, no/
yes, n (%)
22/27 (45/55) 27/23b (54/46) 33/15b (65/35) 16/35 (31/69) < 0.001
Bisphosphonate therapy, no/
yes, n (%)
46/3 (94/6) 42/8b (84/16) 46/2b (90/10) 42/9 (82/18) 0.05
CFRD, no/yes, n (%) 12/37 (24/76) 22/31 (42/58) 23/28 (45/55) 11/40 (22/78)
Exocrine pancreatic 
insufficiency, no/yes, n (%)
46/3 (94/6) 51/2 (96/4) 47/4 (92/8) 50/1 (98/2)
CFTR genotype, n (%)c
Unknown 7 (14) 11 (21) 15 (29) 3 (6)
Known 42 (86) 42 (79) 36 (71) 48 (94)
Severe/Severe 25 (60) 26 (62) 20 (55) 29 (60)
Severe/Mild 11 (26) 15 (36) 15 (42) 13 (27)
Mild/Mild 6 (14) 1 (2) 1 (3) 6 (13)
Estimated 5-year survival, %d 30 (27-34) 30 (27-34) 31 (27-35) 30 (26-33)
BMI: body mass index; 6MWD: six-minute walk distance; CF: cystic fibrosis; CFRD: CF-related diabetes mellitus; 
and CFTR: cystic fibrosis transmembrane conductance regulator. aValues expressed as mean (95% CI), except 
where otherwise indicated. bMedication unknown in 3 patients. cSevere: class I-III mutations; and mild: class IV-VI 
mutations. dIn accordance with Liou et al.(13) 
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femoral neck were higher in the patients with CFRD 
than in those without CFRD (−1.73; 95% CI: −1.74 
to −2.10 vs. −2.30; 95% CI: −1.90 to −2.69; p = 
0.003; OR = 0.13; 95% CI: 0.02-0.67; p = 0.02). 
DISCUSSION
Low BMD is a common comorbidity in CF patients,(16) 
affecting half of our cohort. This result is consistent 
with those of other studies(2,10,17) and shows the high 
prevalence of bone disease in CF patients (and, in our 
particular cohort, in CF patients with end-stage lung 
disease undergoing LTx evaluation). Osteoporosis 
(particularly lumbar spine osteoporosis) was found to 
be more common in male CF patients than in female 
CF patients, as reported elsewhere.(18) 
CF patients with end-stage lung disease are at a 
high risk of low BMD, and numerous cross-sectional 
studies have found a number of factors associated 
with low BMD, including lung function, BMI, and use 
of corticosteroids.(4-6,8,19-21) With regard to age, there 
are conflicting results.(2,3,6,17,19) In our cohort, the 
BMI was found to have a significant impact on BMD 
(particularly in patients evaluated later in the study 
period and at the femoral neck). However, no correlation 
was found between age and low BMD. Given that 
the BMI range was rather narrow in our cohort, this 
seems quite remarkable. Because we did not perform 
detailed body composition analysis, we were unable to 
determine whether there was a relationship between 
BMD and skeletal muscle mass or between BMD and fat 
mass. Decreased physical capacity(4,22) and recurrent 
infections(10,23) are other known contributors to low 
BMD. In our cohort, neither exercise testing (6MWD) 
nor exacerbation frequency in the year before LTx 
evaluation correlated with low BMD. In addition, no 
correlation was found between low BMD and biochemical 
parameters. Vitamin D deficiency reflects malnutrition, 
affecting calcium homeostasis and bone turnover,(16) 
being a common finding in patients with CF. Several 
studies have shown that 25(OH)D is low in patients 
with CF, regardless of age. This is due to malabsorption, 
insufficient production of vitamin D in the skin (which 
is due to decreased exposure to sunlight as a result 
of lower levels of outdoor physical activity), lower 
amount of body fat for storage, decreased quantities 
of vitamin D-binding protein with a shorter half-life, 
and recurrent hospitalizations.(24) Vitamin D deficiency 
can result in secondary hyperparathyroidism, and 
high PTH levels can be associated with low BMD in 
patients with CF. West et al.(25) suggested that PTH 
is a more sensitive predictor of CFBD in CF patients 
than is 25(OH)D. Although the majority of our patients 
showed 25(OH)D levels of < 30 µg/L, there was no 
correlation of 25(OH)D with BMD or low BMD. In 
addition, there was no association of PTH levels with 
Table 3. Biochemical parameters in the cystic fibrosis patients included in the study, by osteoporosis status (i.e., with 
or without osteoporosis).a
Parameter All Without 
osteoporosis
With 
osteoporosis
p Normal 
range
CRP, mg/L 33 (26-40) 31 (19-44) 34 (25-42) < 5
Creatinine, µmol/L 67 (64-70) 65 (61-68) 69 (65-73) 62-106
GFR, mL/min/1.73 km2 92 (88-96) 95 (90-100) 90 (84-96)
Albumin, g/L 36 (35-38) 37 (35-40) 35 (34-37) 40-49
HbA1c, % 6.7 (6.5-6.9) 6.7 (6.4-6.9) 6.6 (6.3-7.0) 4.8-5.9
Fasting glucose, mmol/L 6.5 (5.8-7.2) 6.6 (5.6-6.7) 6.8 (5.6-8.0) < 5.6
Calcium (albumin-corrected), mmol/L 2.36 (2.32-2.40) 2.33 (2.26-2.40) 2.39 (2.36-2.43) 2.09-2.54
Phosphate, mmol/L 1.05 (1.01-1.10) 1.02 (0.95-1.09) 1.08 (1.02-1.14) 0.87-1.45
Alkaline phosphatase, U/L 139 (119-158) 138 (11-164) 140 (11-168) 40-129
Bone alkaline phosphatase, µg/L (n = 83) 15.7 (13.7-17.7) 15.1 (12.7-17.6) 16.4 (13.1-19.6) 3.7-21.1
25(OH)D, µg/L (n = 85) 21 (18-23) 21 (18-25) 20 (16-24) 10-42
25(OH)D < 30 µg/L, no/yes, n (%) 22/63 (26/74) 11/34 (24/76) 11/29 (28/72)
PTH, ng/L (n = 84) 50 (46-61) 50 (40-59) 51 (31-71) 15-65
PTH > 65 ng/L, no/yes, n (%) 73/11 (87/13) 40/4 (91/9) 33/7 (83/17)
Osteocalcin, ng/L (n = 30) 4.3 (3.5-5.0) 4.6 (3.3-5.9) 4.0 (3.1-5.0) 2.4-10.0
Testosterone (in males), nmol/L (n = 34) 13.6 (11.3-15.9) 15.8 (12.3-19.3) 11.7 (8.6-14.8) 7.57-31.4
Estradiol (in females), pmol/L (n = 39) 189 (129-250) 189 (95-283) 190 (110-270)
Urinary calcium/creatinine (n = 78) 0.5 (0.5-0.6) 0.50 (0.39-0.61) 0.55 (0.45-0.65) 0.1-0.5
Urinary calcium/creatinine > 0.5, no/yes, n (%) 46/32 (59/41) 20/16 (56/44) 12/29 (29/71) 0.04
Urinary deoxypyridinoline/creatinine (n = 85) 8.0 (7.0-9.0) 7.7 (6.3-9.1) 8.4 (6.8-9.9) 2.5-5.0
Urinary deoxypyridinoline/creatinine > 5.0, 
no/yes, n (%)
23/62 (27/73) 11/33 (25/75) 12/29 (29/71)
Urinary creatinine/24 h, mmol (n = 90) 8.7 (8.0-9.4) 9.0 (8.1-9.9) 8.5 (7.5-9.5)
CRP: C-reactive protein; GFR: glomerular filtration rate (as calculated by the Cockcroft and Gault equation); 
HbA1c: hemoglobin A1c; 25(OH)D: 25-hydroxyvitamin D; and PTH: parathyroid hormone. aValues expressed as 
mean (95% CI), except where otherwise indicated. 
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25(OH)D levels or low BMD in our patient cohort, a 
finding that is consistent with those of Flohr et al.(5) 
It is of note that secondary hyperparathyroidism was 
found in only 13 patients in our cohort (PTH levels > 
65 ng/L). Neither decreased renal function nor low 
25(OH)D levels led to increased PTH levels in the 
majority of our patients. In addition, PTH was found 
to be an inadequate parameter to detect or monitor 
CFBD; PTH levels did not reflect vitamin D deficiency 
in CF patients with end-stage lung disease and a high 
CFBD prevalence. However, the negative correlation 
between serum levels of albumin-corrected calcium 
and PTH was striking and highly significant. Almost 
10% of the patients had borderline or elevated serum 
levels of albumin-corrected calcium; none had primary 
hyperparathyroidism. Osteocalcin, a serum marker of 
osteoblast activity, has been shown to correlate with 
bone loss.(26) Changes in bone turnover with increased 
bone resorption and altered bone formation have 
been described elsewhere.(16,27,28) However, we found 
no correlation of osteocalcin or deoxypyridinoline 
with BMD, having found only a borderline significant 
correlation with calciuria (as assessed in a fasting spot 
urine sample). Male hypogonadism has been shown to 
be associated with CFBD and vertebral fractures. (29,30) 
Although the prevalence of low BMD was higher in 
males than in females in our cohort, we found no 
correlation between testosterone and BMD. 
Experimental studies have shown that CFTR-null 
mice exhibit severe osteopenia.(31) In a cross-sectional 
study including 88 adult patients with CF, it was 
reported that BMD at the lumbar spine and femoral 
neck is significantly lower in Phe508del homozygous 
or heterozygous patients than in patients without the 
ΔF508 mutation.(17) Aris et al.(32) speculated that CFTR 
mutations can provide a genetic link, directly influencing 
bone cell function. In addition, the CFTR protein has 
recently been shown to be expressed in human bone 
cells, playing an important role in the production of 
osteoprotegerin and prostaglandin E2, both of which 
are key factors in bone formation and regeneration.
(33-35) Jacquot et al. tested a CFTR corrector (miglustat) 
in a Phe508del mutant CF mouse model, showing 
normalized bone volume and improved bone formation(11) 
and raising the question of whether CFTR-targeted 
drugs can act directly on bone cells. In the present 
study, we found no correlation between the Phe508del 
mutation and CFBD. Although CFTR is expressed in 
bone tissue and therefore CF mutation status can 
theoretically influence bone mass density, our data 
clearly demonstrate that, in patients with end-stage 
lung disease, the lung disease itself and pancreatic 
insufficiency (leading to a catabolic metabolism) have 
in general a much broader indirect impact on bone 
health than does CFTR mutation status. 
In the present study, the frequency of low BMD at 
the time of LTx evaluation decreased over time. Low 
BMD was found to be much more common in the earlier 
study period than in the later study period, a finding 
that is consistent with those of other studies. (17,36,37) 
Although this reduction in the incidence of low BMD 
was more pronounced at the femoral neck than at 
the lumbar spine, the latter became more severely 
affected over time than did the former. The patients 
who were evaluated for LTx later in the study period 
had a significantly higher BMI. In addition, vitamin 
D supplementation (alone or in combination with 
bisphosphonate therapy) was more common in those 
patients, whereas systemic corticosteroid therapy was 
less common. Accordingly, 25(OH)D levels tended to 
be higher in those patients. In addition, because CFRD 
was more frequently diagnosed in the later era than in 
the earlier era, insulin treatment was more common 
among the patients who were evaluated for LTx later 
in the study period than among those who were 
evaluated for LTx earlier in the study period, a finding 
that is consistent with those of another study.(38) It is 
of note that BMD at the femoral neck was found to be 
Figure 2. Spearman’s correlation of serum parathyroid hormone (PTH) levels with serum 25-hydroxyvitamin D (25(OH)
D) and (albumin-corrected) calcium levels. NS: not significant. 
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significantly higher in patients with CFRD. Our findings 
are inconsistent with those of a recent study comparing 
patients with moderate CF evaluated in the 1995-1999 
period and those evaluated in the 2011-2013 period,(39) 
with no significant differences in BMD or BMI between 
the two cohorts of patients. Overall, the current practice 
for patients treated at our center has clearly led to a 
remarkable improvement in bone health. Our results 
indicate that awareness of CF as a “multiorgan disease”, 
as well as a focus on improving nutrition and treating 
bone disease, together with early detection of CFRD 
and insulin treatment (systemic corticosteroid therapy 
being avoided), resulted in improved health (including 
bone health) and comorbidities that are less severe in 
our cohort of patients with CF. 
Our study has several strengths. Our cohort 
consisted of CF patients with end-stage lung disease, 
thoroughly evaluated for LTx by using a standardized 
protocol. Therefore, our study provides detailed clinical 
information on a unique and well-studied cohort of 
patients, who were well-matched for lung function, 
performance status (6MWD), relative time to evaluation 
for LTx, and estimated 5-year survival. In comparison 
with other studies with similar sample size, ours involved 
a fairly homogenous cohort of patients with regard to 
lung disease severity. Evaluation of patients at a single 
center allows direct comparison of BMD values over 
a long observation period (i.e., nearly two decades), 
given that DXA machines were calibrated accordingly. 
One limitation of our study is that DXA results were 
reported as T-scores. Z-scores were not available for 
most of the patients evaluated earlier in the study 
period. For reasons of comparability, data on the 
entire cohort were reported as T-scores. Given that 
the study patients were in the 25- to 30-year age 
bracket, T-scores were not expected to result in major 
data distortion. 
CFBD is a common comorbidity in patients with CF 
and can have a severe impact on health status and 
health-related quality of life. The development and 
progression of CF clinical manifestations such as CFBD 
are mainly determined by environmental exposure, 
medical treatment, and therapy adherence, as well 
as CFTR mutation status. The prevalence of low BMD 
in CF lung transplant candidates has decreased in 
recent years, indicating a better understanding of CF 
as a multiorgan disease and improved multidisciplinary 
CF care, including early screening and treatment of 
CF-related comorbidities. In the present study, we 
found no correlation between CFTR mutation status 
and CFBD. In our opinion, lung disease severity and 
pancreatic insufficiency have a much broader (indirect) 
impact on the development of CFBD than does CFTR 
mutation status per se. 
Overall, we were unable to identify a biochemical 
parameter associated with CFBD in CF patients with 
end-stage lung disease (with the possible exception of 
fasting calciuria, reflecting net bone loss). DXA remains 
the only reliable diagnostic tool to evaluate CFBD, 
which is still a prevalent and challenging problem, 
especially in patients with advanced lung disease, 
male patients, and patients with low BMI. In the last 
decade, efforts have been made to prevent and treat 
CFBD accordingly. Our data show that our current 
practice in managing patients with CFBD has lead to 
improved bone health. 
REFERENCES
1. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung 
disease. N Engl J Med. 2015;372(16):1574-5. https://doi.org/10.1056/
NEJMc1502191
2. Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The 
prevalence of osteoporosis, osteopenia, and fractures among 
adults with cystic fibrosis: a systematic literature review with meta-
analysis. Calcif Tissue Int. 2010;86(1):1-7. https://doi.org/10.1007/
s00223-009-9316-9
3. Conway SP, Morton AM, Oldroyd B, Truscott JG, White H, Smith 
AH, et al. Osteoporosis and osteopenia in adults and adolescents 
with cystic fibrosis: prevalence and associated factors. Thorax. 
2000;55(9):798-804. https://doi.org/10.1136/thorax.55.9.798
4. Elkin SL, Fairney A, Burnett S, Kemp M, Kyd P, Burgess J, et al. 
Vertebral deformities and low bone mineral density in adults 
with cystic fibrosis: a cross-sectional study. Osteoporos Int. 
2001;12(5):366-72. https://doi.org/10.1007/s001980170104
5. Flohr F, Lutz A, App EM, Matthys H, Reincke M. Bone mineral 
density and quantitative ultrasound in adults with cystic fibrosis. 
Eur J Endocrinol. 2002;146(4):531-6. https://doi.org/10.1530/
eje.0.1460531
6. Rossini M, Del Marco A, Dal Santo F, Gatti D, Braggion C, James G, 
et al. Prevalence and correlates of vertebral fractures in adults with 
cystic fibrosis. Bone. 2004;35(3):771-6. https://doi.org/10.1016/j.
bone.2004.05.009
7. Grey V, Atkinson S, Drury D, Casey L, Ferland G, Gundberg C, et 
al. Prevalence of low bone mass and deficiencies of vitamins D and 
K in pediatric patients with cystic fibrosis from 3 Canadian centers. 
Pediatrics. 2008;122(5):1014-20. https://doi.org/10.1542/peds.2007-
2336
8. Legroux-Gérot I, Leroy S, Prudhomme C, Perez T, Flipo RM, 
Wallaert B, et al. Bone loss in adults with cystic fibrosis: prevalence, 
associated factors, and usefulness of biological markers. Joint Bone 
Spine. 2012;79(1):73-7. https://doi.org/10.1016/j.jbspin.2011.05.009
9. Tschopp O, Boehler A, Speich R, Weder W, Seifert B, Russi 
EW, et al. Osteoporosis before lung transplantation: association 
with low body mass index, but not with underlying disease. Am 
J Transplant. 2002;2(2):167-72. https://doi.org/10.1034/j.1600-
6143.2002.020208.x
10. Ionescu AA, Nixon LS, Evans WD, Stone MD, Lewis-Jenkins V, 
Chatham K, et al. Bone density, body composition, and inflammatory 
status in cystic fibrosis. Am J Respir Crit Care Med. 2000;162(3 Pt 
1):789-94. https://doi.org/10.1164/ajrccm.162.3.9910118
11. Jacquot J, Delion M, Gangloff S, Braux J, Velard F. Bone disease 
in cystic fibrosis: new pathogenic insights opening novel therapies. 
Osteoporos Int. 2016;27(4):1401-1412. https://doi.org/10.1007/
s00198-015-3343-3
12. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, 
et al. International guidelines for the selection of lung transplant 
candidates: 2006 update--a consensus report from the Pulmonary 
Scientific Council of the International Society for Heart and Lung 
Transplantation. J Heart Lung Transplant. 2006;25(7):745-55. https://
doi.org/10.1016/j.healun.2006.03.011
13. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall 
BC. Predictive 5-year survivorship model of cystic fibrosis. Am J 
Epidemiol. 2001;153(4):345-52. https://doi.org/10.1093/aje/153.4.345
14. Soulsby N, Greville H, Coulthard K, Doecke C. What is the best 
method for measuring renal function in adults and children with cystic 
fibrosis? J Cyst Fibros. 2010;9(2):124-9. https://doi.org/10.1016/j.
jcf.2009.12.002
15. Dimai HP. Use of dual-energy X-ray absorptiometry (DXA) for 
diagnosis and fracture risk assessment; WHO-criteria, T- and 
Z-score, and reference databases. Bone. 2017;104:39-43. https://doi.
J Bras Pneumol. 2019;45(1):e20170280 7/8
Evaluation of bone disease in patients with cystic fibrosis and end-stage lung disease
org/10.1016/j.bone.2016.12.016
16. Aris RM, Ontjes DA, Buell HE, Blackwood AD, Lark RK, Caminiti M, 
et al. Abnormal bone turnover in cystic fibrosis adults. Osteoporos 
Int. 2002;13(2):151-7. https://doi.org/10.1007/s001980200007
17. King SJ, Topliss DJ, Kotsimbos T, Nyulasi IB, Bailey M, Ebeling PR, et 
al. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an 
independent risk factor. Eur Respir J. 2005;25(1):54-61. https://doi.or
g/10.1183/09031936.04.00050204
18. Baker JF, Putman MS, Herlyn K, Tillotson AP, Finkelstein JS, Merkel 
PA. Body composition, lung function, and prevalent and progressive 
bone deficits among adults with cystic fibrosis. Joint Bone Spine. 
2016;83(2):207-11. https://doi.org/10.1016/j.jbspin.2015.04.021
19. Laursen EM, Molgaard C, Michaelsen KF, Koch C, Müller J. Bone 
mineral status in 134 patients with cystic fibrosis. Arch Dis Child. 
1999;81(3):235-40. https://doi.org/10.1136/adc.81.3.235
20. Gronowitz E, Garemo M, Lindblad A, Mellström D, Strandvik 
B. Decreased bone mineral density in normal-growing patients 
with cystic fibrosis. Acta Paediatr. 2003;92(6):688-93. https://doi.
org/10.1111/j.1651-2227.2003.tb00601.x
21. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density 
and body composition in adult patients with cystic fibrosis. Thorax. 
1993;48(6):589-93. https://doi.org/10.1136/thx.48.6.589
22. Frangolias DD, Holloway CL, Vedal S, Wilcox PG. Role of exercise and 
lung function in predicting work status in cystic fibrosis. Am J Resp 
Crit Care. 2003;167(2):150-7. https://doi.org/10.1164/rccm.2202053
23. Shead E, Haworth C, Barker H, Gunn E, Bilton D, Scott M, et 
al. Alterations in bone metabolism occur at times of infective 
exacerbation in adults with cystic fibrosis. Thorax. 2006;61:Ii35-Ii.
24. Javier RM, Jacquot J. Bone disease in cystic fibrosis: what’s new? 
Joint Bone Spine. 2011;78(5):445-50. https://doi.org/10.1016/j.
jbspin.2010.11.015
25. West NE, Lechtzin N, Merlo CA, Turowski JB, Davis ME, Ramsay 
MZ, et al. Appropriate goal level for 25-hydroxyvitamin D in cystic 
fibrosis. Chest. 2011;140(2):469-474. https://doi.org/10.1378/
chest.10-2114
26. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein 
HP. The course of biochemical parameters of bone turnover 
during treatment with corticosteroids. J Clin Endocrinol Metab. 
1991;72(2):382-6. https://doi.org/10.1210/jcem-72-2-382
27. Gordon CM, Binello E, LeBoff MS, Wohl ME, Rosen CJ, 
Colin AA. Relationship between insulin-like growth factor I, 
dehydroepiandrosterone sulfate and proresorptive cytokines and 
bone density in cystic fibrosis. Osteoporos Int. 2006;17(5):783-90. 
https://doi.org/10.1007/s00198-005-0058-x
28. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin 
SL, et al. Guide to bone health and disease in cystic fibrosis. J Clin 
Endocrinol Metab. 2005;90(3):1888-96. https://doi.org/10.1210/
jc.2004-1629
29. Donovan DS Jr, Papadopoulos A, Staron RB, Addesso V, Schulman 
L, McGregor C, et al. Bone mass and vitamin D deficiency in 
adults with advanced cystic fibrosis lung disease. Am J Respir 
Crit Care Med. 1998;157(6 Pt 1):1892-9. https://doi.org/10.1164/
ajrccm.157.6.9712089
30. Leifke E, Friemert M, Heilmann M, Puvogel N, Smaczny C, von zur 
Muhlen A, et al. Sex steroids and body composition in men with 
cystic fibrosis. Eur J Endocrinol. 2003;148(5):551-7. https://doi.
org/10.1530/eje.0.1480551
31. Dif F, Marty C, Baudoin C, de Vernejoul MC, Levi G. Severe 
osteopenia in CFTR-null mice. Bone. 2004;35(3):595-603. https://doi.
org/10.1016/j.bone.2004.05.021
32. Aris RM, Guise TA. Cystic fibrosis and bone disease: are we missing 
a genetic link? Eur Respir J. 2005;25(1):9-11. https://doi.org/10.1183
/09031936.04.00125804
33. Le Heron L, Guillaume C, Velard F, Braux J, Touqui L, Moriceau S, 
et al. Cystic fibrosis transmembrane conductance regulator (CFTR) 
regulates the production of osteoprotegerin (OPG) and prostaglandin 
(PG) E2 in human bone. J Cyst Fibros. 2010;9(1):69-72. https://doi.
org/10.1016/j.jcf.2009.11.005
34. Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, 
Compston JE. Cystic fibrosis transmembrane conductance regulator 
(CFTR) is expressed in human bone. Thorax. 2007;62(7):650-1. 
https://doi.org/10.1136/thx.2006.075887
35. Gimenez-Maitre A, Le Henaff C, Norez C, Guillaume C, Ravoninjatovo 
B, Laurent-Maquin D, et al. Deficit of osteoprotegerin release 
by osteoblasts from a patient with cystic fibrosis. Eur Respir J. 
2012;39(3):780-1. https://doi.org/10.1183/09031936.00104111
36. Le Henaff C, Haÿ E, Velard F, Marty C, Tabary O, Marie PJ, et 
al. Enhanced F508del-CFTR channel activity ameliorates bone 
pathology in murine cystic fibrosis. Am J Pathol. 2014;184(4):1132-
1141. https://doi.org/10.1016/j.ajpath.2013.12.027
37. Stephenson A, Jamal S, Dowdell T, Pearce D, Corey M, Tullis E. 
Prevalence of vertebral fractures in adults with cystic fibrosis and 
their relationship to bone mineral density. Chest. 2006;130(2):539-
44. https://doi.org/10.1378/chest.130.2.539
38. Hofer M, Schmid C, Benden C, Speich R, Inci I, Weder W, et al. 
Diabetes mellitus and survival in cystic fibrosis patients after 
lung transplantation. J Cyst Fibros. 2012;11(2):131-6. https://doi.
org/10.1016/j.jcf.2011.10.005
39. Putman MS, Baker JF, Uluer A, Herlyn K, Lapey A, Sicilian L, et al. 
Trends in bone mineral density in young adults with cystic fibrosis 
over a 15 year period. J Cyst Fibros. 2015;14(4):526-32. https://doi.
org/10.1016/j.jcf.2015.01.011
J Bras Pneumol. 2019;45(1):e201702808/8
